FDA seeks injunction against two stem cell clinics in first move against unregulated industryBMJ 2018; 361 doi: https://doi.org/10.1136/bmj.k2162 (Published 16 May 2018) Cite this as: BMJ 2018;361:k2162
- Owen Dyer
The US Food and Drug Administration is seeking a permanent injunction to shut down the operations of two companies offering unproven stem cell treatments.
FDA commissioner Scott Gottlieb said that the US Stem Cell Clinic in Florida, the Cell Surgical Network in California, and others like them are exploiting desperate patients. “Cell based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk,” he said.
“In some instances, patients have suffered serious and permanent harm after receiving these unapproved products. In the two cases filed today, the clinics and their leadership have continued to disregard the …